A live attenuated version of the ZIKV vaccine has been shown to enter GBM tumor cells via αvβ5 and/or Ax1 receptors, which in turn induce apoptosis (caspase-3) and pyroptosis (GSDMD/IL-1β). Here, CASP3 is linked to neoplasm.